// App-Quantinova.ai

126 : Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.

Researchers

Presenter

  • Johann S. De Bono

Principal Investigators

  • Nicolas Penel

  • Niven Mehra

  • Michael Paul Kolinsky

  • Emmanuelle Bompas

  • Susan Feyerabend

  • Gwenaelle Gravis

  • Jae Young Joung

  • Kazuo Nishimura

  • Craig Gedye

  • Joaquin Mateo

  • Fred Saad

  • Karim Fizazi

  • Neal Shore

  • Jinyu Kang

  • Chintu Desai

  • Joseph E. Burgents

  • Elizabeth Harrington

  • Maha H. A. Hussain

Medical Centers

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • National Cancer Center Hospital, Tokyo, Japan

  • Centre Oscar Lambret, Lille, France

  • Radboud University Medical Center, Njmegen, Netherlands

  • Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Urologic Oncology, Studienpraxis Urologie, Nürtingen, Germany

  • Institut Paoli-Calmettes, Marseille, France

  • Center for Liver Cancer, National Cancer Center, Goyang, Korea

  • Department of Gynecology, Osaka International Cancer Institute, Osaka, Japan

  • Calvary Mater Newcastle, Waratah, NSW, Australia

  • Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • AstraZeneca, Gaithersburg, MD

  • Merck & Co., Inc., Kenilworth, NJ

  • AstraZeneca Translational Medicine, Early Oncology, Cambridge, United Kingdom

  • Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

Locations

  • United Kingdom

  • Japan

  • France

  • Netherlands

  • Canada

  • Germany

  • Republic of South Korea

  • Australia

  • Spain

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Hormone receptor

  • BRCA mutation

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02987543

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved